Overview

Chiglitazar Added to Metformin for Type 2 Diabetes

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Chipscreen Biosciences, Ltd.
Treatments:
Metformin